Samaritan Pharmaceuticals, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1994-01-01
- Employees
- 11
- Market Cap
- -
Clinical Trials
3
Active:0
Completed:1
Trial Phases
2 Phases
Phase 1:1
Phase 2:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 2
2 (66.7%)Phase 1
1 (33.3%)SP01A: The Study of an Oral Entry Inhibitor in Treatment-Experienced HIV Patients
Phase 2
- Conditions
- HIV InfectionsHuman Immunodeficiency Virus
- First Posted Date
- 2006-03-07
- Last Posted Date
- 2006-10-27
- Lead Sponsor
- Samaritan Pharmaceuticals, Inc
- Target Recruit Count
- 60
- Registration Number
- NCT00299897
- Locations
- 🇺🇸
AIDS Healthcare Foundation, Beverly Hills, California, United States
🇺🇸Therafirst Medical Centers, Fort Lauderdale, Florida, United States
🇺🇸Infectious Disease of Central Florida, Orlando, Florida, United States
A Dose Response and Safety Study of Procaine HCl in HIV-Infected Patients
Phase 1
Completed
- Conditions
- HIV Infections
- First Posted Date
- 2006-03-06
- Last Posted Date
- 2006-04-03
- Lead Sponsor
- Samaritan Pharmaceuticals, Inc
- Target Recruit Count
- 24
- Registration Number
- NCT00299338
- Locations
- 🇺🇸
AIDS Research Alliance of West Hollywood, West Hollywood, California, United States
A Study of an Oral Entry Inhibitor, SP01A, in Treatment-Experienced HIV-Infected Patients
Phase 2
- Conditions
- HIV Infections
- First Posted Date
- 2005-06-08
- Last Posted Date
- 2006-03-22
- Lead Sponsor
- Samaritan Pharmaceuticals, Inc
- Target Recruit Count
- 32
- Registration Number
- NCT00113412
- Locations
- 🇺🇸
Therafirst Medical Centers, Fort Lauderdale, Florida, United States
🇺🇸BioCollections Worldwide, Inc., Miami, Florida, United States
🇺🇸Orlando Immunology Center, Orlando, Florida, United States
News
No news found